

For Immediate Release
For Further Information Contact:
Andrew Fisher at (301) 608-9292
Email: Afisher@unither.com

**DATA FROM TWO-YEAR EXPERIENCE WITH REMODULIN
PRESENTED AT INTERNATIONAL SOCIETY OF HEART AND LUNG
TRANSPLANTATION ANNUAL MEETING IN VIENNA**

Silver Spring, MD, April 14, 2003: United Therapeutics Corporation (NASDAQ:UTHR) announced today that a team of eight doctors presented a paper entitled “*Two-Year Experience with Continuous Subcutaneous Treprostinil (Prostacyclin Stable Analogue) in Severe Pulmonary Hypertension Treatment*” at the International Society of Heart and Lung Transplantation Annual Meeting in Vienna, Austria on April 11, 2003. The paper concluded, “In patients with severe pulmonary hypertension, long-term therapy with treprostinil (Remodulin) (1) improves NYHA function class and exercise tolerance and (2) improves long term survival and (3) there were no severe side effects related to the delivery system.” The abstract for the paper is published in the January 2003 issue of the *JOURNAL OF HEART AND LUNG TRANSPLANTATION*.

“We are very pleased to see ever-longer periods of satisfactory experience with Remodulin,” said Martine Rothblatt, Ph.D., Chairman and CEO of United Therapeutics. “We gain much inspiration from the knowledge that Remodulin is proving so helpful to clinicians in treating their patients with pulmonary arterial hypertension.”

Remodulin received United States Food and Drug Administration approval on May 21, 2002 for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise. In clinical trials, the most common side effects reported with Remodulin therapy included infusion site pain (85%) and infusion site reaction (83%). Other adverse events included headache (27%), diarrhea (25%), nausea (22%), rash (14%), jaw pain (13%), vasodilatation (11%), dizziness (9%), edema (9%), pruritus (8%) and hypotension (4%). Remodulin should be used only by clinicians experienced in the diagnosis and treatment of PAH.

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncological diseases with unique therapeutic products.

* * *